Valuation: Cybin Inc.

Market Cap 665M 472M 415M 386M 354M 45.48B 675M 4.58B 1.79B 22.36B 1.77B 1.73B 77.32B P/E 2027 *
-2.84x
P/E 2028 * -3.36x
Enterprise Value 229M 162M 143M 133M 122M 15.65B 232M 1.58B 616M 7.69B 610M 597M 26.6B EV / Sales 2027 *
-
EV / Sales 2028 * 18.8x
Free-Float
97.25%
Yield 2027 *
-
Yield 2028 * -

Last Transcript: Cybin Inc.

Manager TitleAgeSince
Chief Operating Officer 37 2016-10-12
Chief Executive Officer 51 2026-04-19
Director of Finance/CFO 56 2020-11-04
Director TitleAgeSince
Chairman 51 2020-11-04
Director/Board Member 37 2016-10-12
Director/Board Member 65 2020-11-04
Change 5-day change 1-year change 3-year change Capi.($)
-6.07%+17.41% - - 472M
+0.93%+6.97%+62.83%+67.97% 57.28B
-1.92%+6.03%+43.68%+84.56% 54.99B
-0.46%-1.29%+3.28%+422.58% 23.18B
-2.97%-2.35%-22.03%-16.54% 22.59B
-0.36%+5.73%+30.99%-3.58% 20.46B
-1.34%+0.51%+25.02%-30.27% 17.56B
-1.44%+5.67%+32.54%+544.11% 15.67B
-1.30%-5.02%+165.62%+291.37% 14.46B
-0.50%-0.98%+23.62%+178.38% 13.92B
Average -1.54%+1.28%+40.62%+170.95% 26.68B
Weighted average by Cap. -0.88%+2.10%+41.18%+135.69%

Financials

2027 *2028 *
Net sales - 3.65M 2.59M 2.28M 2.12M 1.94M 250M 3.71M 25.14M 9.82M 123M 9.73M 9.52M 424M
Net income -251M -178M -157M -146M -134M -17.17B -255M -1.73B -676M -8.44B -669M -655M -29.19B -275M -195M -171M -159M -146M -18.8B -279M -1.89B -740M -9.24B -733M -717M -31.95B
Net Debt -436M -310M -272M -253M -232M -29.84B -443M -3.01B -1.17B -14.67B -1.16B -1.14B -50.72B -596M -423M -372M -346M -317M -40.78B -606M -4.11B -1.6B -20.05B -1.59B -1.56B -69.32B
Logo Cybin Inc.
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
10.73CAD
Average target price
52.92CAD
Spread / Average Target
+393.15%

Quarterly revenue - Rate of surprise